Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › filgotinib

filgotinib

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of filgotinib

15 trials tracked of filgotinib: 5 in phase 3 or 4 and 5 with published results. The most-cited published study has 337 citations.

15Trials tracked
5Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 5 Phase 2 8 Phase 1 2
  1. Phase 3 Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment Completed · 337 cited
  2. Phase 3 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Completed · 20 cited
  3. Phase 3 Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Completed · 12 cited
  4. Phase 3 Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy Completed · 12 cited
  5. Phase 3 Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Completed · 7 cited
  6. Phase 2 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease Completed
Show 9 more trials
  1. Phase 2 Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate Completed
  2. Phase 2 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) Completed
  3. Phase 2 Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Completed
  4. Phase 2 Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome Completed
  5. Phase 2 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) Completed
  6. Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis Completed
  7. Phase 2 Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants Completed
  8. Phase 1 Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants Completed
  9. Phase 1 Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Cardiovascular risk for Janus kinase inhibitors in rheumatoid arthritis remains inconsistent across specific molecules
Drug Pipeline Sys. Review
Cardiovascular risk for Janus kinase inhibitors in rheumatoid arthritis remains inconsistent across specific molecules New data reveals specific risks for some rheumatoid arthritis drugs
This narrative review examines the cardiovascular safety of Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis and other …
New data shows that one specific rheumatoid arthritis drug carries a higher risk of heart problems for some patients.
Frontiers Sep 14, 2026
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis
Rheumatology Sys. Review
Combination therapies with adalimumab, infliximab, tofacitinib, or upadacitinib increase serious infection risk in rheumatoid arthritis New data shows infection risks for rheumatoid arthritis treatments
This meta-analysis of 55,749 patients with rheumatoid arthritis found that while b/tsDMARD monotherapy carries a similar risk of serious inf…
New research highlights how combining certain medications for rheumatoid arthritis can increase the risk of serious infections.
Jul 18, 2026
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months
Psychiatry Cohort
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Frontiers Apr 16, 2026